Elanco Gets Investors’ Dog Itch Drug Development Suit Dismissed

Elanco Animal Health Inc. defeated investor allegations it hid a study raising safety issues that would impact the regulatory approval timeline and commercial launch of a canine itch treatment.

The investors leading the case failed to sufficiently allege Elanco or top executives knowingly misled investors by not disclosing a study of dermatitis drug Zenrelia’s effect on canine vaccination responses, Judge Brendan A. Hurson said Thursday, dismissing the proposed class action without the ability to replead.

Elanco didn’t mention the study or its results that would ultimately delay the drug’s US Food and Drug Administration approval and cause it to have ...